CD33 and acute myeloid leukemia: CD33 is broadly expressed on AML blasts and leukaemic stem cells (LSCs) and has been targeted using the drug conjugated humanised anti-CD33 monoclonal antibody (mAb) Gemtuzumab ozogamicin (GO) [25, 26].